Following subcutaneous inoculation of newborn Wistar-Furth rats with human adenovirus type 9 (Ad9), 16 of 16 female and 0 of 11 male rats developed mammary tumors. Tumor-positive animals usually developed tumors in multiple glands. Histopathological analyses indicated that three general categories of tumor could be identified. Mammary fibroadenomas were the most common tumor type encountered, but phyllodeslike tumors and solid sarcomas were also frequently found. In situ hybridization and immunohistochemical techniques established that benign fibroadenomas were derived from mammary fibroblasts (collagen type I-and vimentin-positive cells) and that malignant tumors were derived from myoepithelial cells (collagen type IV-, vimentin-, and muscle-specific actin-positive cells). The fact that mammary tumors were limited to female rats suggested that female hormones are essential for tumor growth and development. In this regard, ovariectomy of Ad9-infected female rats prevented tumor development, while subsequent diethylstilbestrol (DES) treatment elicited tumor formation. In addition, Ad9-infected and castrated male rats which received DES also developed mammary tumors. Established male mammary tumors regressed when DES treatment was stopped and reappeared after DES treatment was resumed. Together, these results indicate that estrogen is required for both initiation and maintenance of Ad9-induced mammary tumors. Southern blot analysis of high-molecularweight tumor DNA showed that mammary tumor cells contained single or multiple integrated copies of the entire Ad9 genome. RNase protection experiments established that estrogen receptor as well as Ad9 Ela and E4 mRNAs were expressed in mammary tumors, but Ad9 E3 and, surprisingly, Elb mRNAs were not expressed at detectable levels.
Human adenovirus type 9 (Ad9) is a member of the subgroup D adenoviruses, which includes 20 different serotypes (48) . In humans, some subgroup D viruses, including viruses closely related to Ad9, cause epidemic eye infections (1, 29, 37, 53) , but in general, very little is known about these viruses.
Subgroup D viruses are classified as nononcogenic because they do not induce tumors following injection into newborn hamsters (50) . Their ability to morphologically transform primary rodent cells in culture remains controversial. It was originally reported that several members of the subgroup D family, including Ad9, can morphologically transform primary Fisher rat embryo fibroblasts (REF) (36) . In contrast, more recent studies suggest that transfection of Ad9 viral DNA into primary Fisher baby rat kidney (BRK) cells does not result in morphologically transformed foci (27) . Ad9, however, is clearly able to transform established rat fibroblast cell lines. Rat 3Y1 cells, an established Fisher REF cell line, are efficiently transformed by Ad9 (12) , and these Ad9-transformed cells typically contain multiple, tandemly integrated copies of the entire virus genome. As would be expected for an adenovirus, the ability of Ad9 to transform established rat fibroblasts maps to the left end of the viral DNA, since CREF cells (another established Fisher REF cell line) can be transformed by a cloned DNA fragment representing the left-most 20% of the virus genome (27) .
Although the subgroup D adenoviruses are classified as Ad9-INDUCED MAMMARY TUMORS   3193 In the present study, we confirm previous work regarding Ad9-induced tumorigenesis in W/Fu rats and make several new observations. First, Ad9-induced mammary tumors fall into three general histological categories-fibroadenoma, phyllodeslike tumor, and solid sarcoma. Second, they are derived from mammary fibroblasts (benign tumors) or myoepithelial cells (malignant tumors). Third, the histologic characteristics of the tumors (benign versus malignant) do not change with time. Fourth, the tumors require estrogen for both initiation and maintenance. Fifth, tumor cells contain single or multiple integrated copies of the entire Ad9 virus genome. Sixth, the tumor cells express detectable estrogen receptor and Ad9 Ela and E4 but not Elb or E3 mRNAs.
MATERIALS AND METHODS
Viruses and cells. A549 cells were maintained as monolayers in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum and supplemented with penicillin and streptomycin. A seed stock of human Ad9 (Hicks strain) was obtained from the American Type Culture Collection (Rockville, Md.) and plaque-purified by limiting dilution on A549 cells. High-titer Ad9 stocks were obtained by multiple serial undiluted passages of the virus on A549 cells. When the infected cells showed maximal cytopathic effect (usually 48 to 72 h postinfection), virus was released from the cells by a single freeze and thaw cycle followed by 1 min of sonication at 0°C. Virus numbers in infected-cell lysates were counted on A549 cells, and plaques were counted 15 to 21 days postinfection. Virus-containing infected-cell lysates were stored at -80°C for later use.
Plasmids. For the Ad9 Ela plasmid, the Ad9 SpeI-NcoI fragment (1 to 936 nucleotides [nt] from the left end) was cloned into pGEM5Zf(+). The SpeI site was created by ligating SpeI linkers to the end of virus DNA as described previously (23) . For production of Ad9 Ela-specific antisense RNA, the plasmid was digested with SspI (site at 763 nt). For the Ad9 Elb plasmid, the Ad9 NaeI-HincII fragment (nt 1628 to 1885 from left end) was cloned into the NaeI and EcoRI (blunt-ended with Klenow) sites of pGEM-3. For production of Ad9 Elb-specific antisense RNA, the plasmid was digested with NaeI. For the Ad9 E4 plasmid, the Ad9 KpnI-EcoRI fragment (nt 789 to 1734 from the right end) was cloned into pGEM-3. For production of Ad9 E4-specific antisense RNA, the plasmid was digested with RsaI (nt 1479). For the Ad9 E3 plasmid, the Ad9 PstI-PstI fragment (approximate map units 74 to 77) was cloned into pGEM3Zf(+). For production of Ad9 E3-specific antisense RNA, the plasmid was digested with NcoI (76 map units). All Ad9 clones were confirmed to be genuine by complete or partial sequence analysis (not shown).
The rat estrogen receptor (rER) cDNA was cloned by reverse transcription of Ad9-induced mammary tumor RNA followed by polymerase chain reaction (PCR) amplification with rER-specific (30) oligonucleotide primers as follows. For the isolation of total RNA, snap-frozen tumors were crushed into a fine powder as described above, and total RNA was prepared. Briefly, the tumor powder was dissolved in tissue guanidinium solution (5 M guanidinium isothiocyanate, 50 mM Tris-HCl [pH 7 .5], 10 mM EDTA, 5% ,-mercaptoethanol), vortexed vigorously, and cleared by centrifugation at 12,500 x g for 10 min at 12°C. The resulting supernatant was drawn rapidly three times through a 20-gauge needle to shear the DNA, made to a final concentration of 2% N-lauryl sarcosine, and heated at 65°C for 2 min. Following the addition of 0.1 g of CsCl per ml of solution, the RNA was pelleted through a 1.5-ml 5.7 M CsCl cushion by centrifugation at 120,000 x g for 14 h at 15°C. The resulting RNA pellet was dissolved in 0.2 ml of tissue resuspension buffer (5 mM EDTA, 0.5% N-lauryl sarcosine, 5% f3-mercaptoethanol), extracted with Tris-buffered phenol and chloroform, and ethanol precipitated.
Isolation of Ad9 virion DNA. Twelve 100-mm tissue culture dishes of A549 cells were infected with Ad9, and when extensive cytopathic effect was evident, the cells were harvested and pelleted (1,500 x g for 10 min at 4°C). The infected-cell pellets were pooled, frozen and thawed once, and sonicated for 3 min at 0°C. This infected-cell lysate was cleared of debris by centrifugation (1,500 x g for 10 min at 4°C), layered over a CsCl step gradient (3 ml of 1.25-g/ml CsCl over 3 ml of 1.4-g/ml CsCl), and centrifuged at 160,000 X g for 1 h at 14°C. The virion band was collected with a syringe needle and purified a second time by mixing with 11 ml of 1.34-g/ml CsCl and centrifuging at 160,000 x g for 16 groups 1 and 3 ). Tumors were first detected when the animals were about 3 months old, and all females had palpable tumors by 5 months of age. Tumors were subcutaneous on the ventral body surface near one of the 12 mammary glands. Most rats developed multiple mammary tumors, some of which grew to huge dimensions (>5 cm in diameter) after several months. As has been reported previously (4, 28) , only mammary tumors were observed, and the tumors were neither metastatic nor lifethreatening.
Three histological classes of mammary tumors are induced by Ad9. H&E-stained mammary tumor tissue sections were examined histologically (Fig. 1) . The most frequently encountered tumors were benign mammary fibroadenomas, as reported earlier (4). These tumors were contained within a well-defined capsule and moved freely beneath the skin. Histologically, they showed a sparse cellular stroma embedded within a dense extracellular matrix which was interspersed with various amounts of ductal and alveolar epithelium (Fig. 1A) .
The second histological tumor type, not previously reported for Ad9, resembled a phyllodeslike tumor (cystosarcoma phyllodes), which is a rare breast tumor found in women (39) . Two variants of this tumor were identified. In the first type, the overall cellular architecture was similar to that of the fibroadenoma but showed increased stromal cellularity (Fig. 1B) . The second variant exhibited a highly atypical stroma with mitoses and was identified as a malignant phyllodeslike tumor (Fig. 1C) . Both the benign and malignant forms of the phyllodeslike tumor contained benign ductal and alveolar elements.
The third tumor type elicited in Ad9-infected rats was a solid sarcoma (Fig. 1D ). less than the reconstruction value of one Ad9 genome per cell (Fig. 2, tumors 2, 9, 10, 12u, and 12x) . We believe that these tumors consist of a mixture of tumor and nontumor cells. By performing reconstructions with known amounts of Ad9 virus DNA, we estimate that 30 to 50% of the cells from these tumors contain a single entire integrated copy of Ad9 virus DNA (not shown).
As shown in lane 4, the solid sarcoma (tumor 8) contained high levels of Ad9 DNA. Multiple integrated virus genomes are present within each cell of this tumor, since we can detect a virus DNA fragment with the predicted size of a head-to-tail linkage of the right and left ends of the virus genome as well as two independent left-end integration junction fragments (data not shown). High Ad9 DNA copy number does not seem, however, to be a requirement for malignant tumors in general, since two malignant phyllodeslike tumors studied contained only a single integrated copy of the Ad9 genome in the tumor cells (Fig. 2, tumor 12x , and not shown). To date, all benign fibroadenomas analyzed contain a single integrated copy (Fig. 2, and (20) . Also (Fig. 2) . Perhaps viral mRNA expression within tumor cells is dependent on a specific stage of the cell cycle.
Expression of Ad9 Ela and E4 mRNAs was also examined in solid sarcomas (Fig. 4E and 4F ). As with fibroadenomas and phyllodeslike tumors, only a small fraction of cells from the solid sarcoma expressed viral mRNAs at levels that could be detected by in situ hybridization. We (20 ,ug per lane). Lanes: Ad9, 3 ng of total RNA isolated from Ad9-infected A549 cells (9 h postinfection).
Numbered tumors are explained in the legend to Fig. 2. expressed vimentin, an antigen specific for stromal cells in general, but did not express detectable levels of cytokeratins, which are found predominantly in epithelial cells (Table  2 ). It is known that mammary fibroblasts specifically express collagen type I and that mammary myoepithelial cells specifically express collagen type IV as well as muscle-specific actin (14, 52) . The stromal cells of five of five benign fibroadenomas expressed collagen type I but did not express collagen type IV. In contrast, three of three malignant phyllodeslike tumors were found to express collagen type IV and muscle-specific actin ( Table 2) . The one solid sarcoma tested was positive for collagen type IV, while one of the three malignant phyllodeslike tumors also expressed epithelial membrane antigen (54) . The heterogeneous antigen profiles of the malignant myoepithelial cells may result from the fact that intermediate variants between epithelial and myoepithelial cells exist in vivo and in vitro (41) .
Further evidence regarding the origin of the malignant tumor cells was provided by electron microscopy. Two malignant phyllodeslike tumors were examined and found to exhibit basal lamina, a characteristic of myoepithelial cells, which is not produced by mammary fibroblasts (data not shown). Interestingly, the one benign phyllodeslike tumor examined contained a mixture of collagen type I-and IVexpressing cells (not shown). Therefore, while the cell type origin leading to benign phyllodeslike tumors was not established, it appears that Ad9 targets mammary fibroblasts to elicit benign fibroadenomas and myoepithelial cells to elicit malignant tumors.
DISCUSSION
In this study, we have examined the histology, estrogen dependence, viral DNA and RNA, and cell types of Ad9-induced mammary tumors in W/Fu rats, and we reached several new conclusions. First, besides fibroadenomas and solid sarcomas, Ad9 also induces a phyllodeslike tumor (Fig.  1) . Presently, Ad9 infection of W/Fu rats represents the only model system for the study of cystosarcoma phyllodes, a rare breast tumor of women (39) . Second, the mammary tumors are estrogen dependent not only for initiation, but also for maintenance (Table 1) . Third, the mammary tumors J. VIROL. contain one or multiple integrated copies of the entire Ad9 genome (Fig. 2) . Fourth, the mammary tumors express detectable estrogen receptor and Ad9 Ela and E4, but not Ad9 Elb or E3 mRNA ( Fig. 3 and 4) . Fifth, both fibroblasts (fibroadenomas) and myoepithelial cells (malignant tumors) are the targeted mammary cells for Ad9 tumorigenesis (Fig.  4 and Table 2 ). We have also confirmed previous results concerning specific induction of mammary tumors in female W/Fu rats by Ad9 (4) and the estrogen dependence of these mammary tumors (3, 33a (Fig. 1) . Jonsson and Ankerst (28) , who originally characterized Ad9 tumorigenesis, reported finding many types of malignant tumors, including round cell liposarcomas, osteosarcomas, and malignant mesenchymomas. We can only speculate that factors such as the source of W/Fu rats, rat diet, type of cells used to propagate Ad9, and the fact that we used a plaque-purified derivative of Ad9 might contribute to these differences.
In some respects, nitrosomethylurea (NMU) carcinogenesis resembles Ad9 carcinogenesis in female rats. A single injection of NMU into female rats elicits mammary tumors with high incidence (22) . Unlike Ad9 tumorigenesis, however, mostly adenocarcinomas are produced, but depending on the dose of NMU given, some fibroadenomas do arise (40) . These tumors seem to arise predominantly as a result of a single point mutation within the ras oncogene (31, 49) . In the NMU-induced mammary tumor system (6, 55) , as with Ad9-induced mammary tumors (Table 1) , estrogen is required for both tumor initiation and maintenance. We do not yet know whether the Ad9-induced mammary tumors contain ras mutations as well, but we think it unlikely since these tumors already express at least one viral oncogene, Ela. It is also worth mentioning that the A2 strain of polyomavirus induces estrogen-dependent mammary adenocarcinomas in female nude mice (9) . Interestingly, in this particular system, estrogen is required only for initiation of the mammary carcinomas, since subsequent hormone withdrawal does not lead to tumor regression.
The molecular analyses of Ad9-induced mammary tumors have provided both familiar and unexpected results. As with most Ad12-induced tumors (20) and Ad9-transformed 3Y1 cells (12) , the mammary tumors elicited by Ad9 contain the entire virus genome integrated into the cellular DNA. Equally familiar is the finding that Ad9 Ela mRNA is expressed, since this gene is invariably detected in adenovirus-induced tumors. Furthermore, in tumors containing the right end of the adenovirus genome, it is not unusual to find expression of E4 mRNA or an E4-derived T antigen (13, 16, 17, 35, 42) . The fact that both Ad9 Ela and E4 mRNAs are expressed in all mammary tumors examined raises the possibility that, besides Ela, E4 also contributes to mammary oncogenesis. Others have shown that the E4 gene product can contribute to soft-agar growth of transformed cells in vitro (46) , and studies with Adl2 (38) and Ad5-Adl2 recombinant viruses (10, 44) (15, 25) . This would bypass the need for the adenovirus Elb 55-kDa
